T&R Biofab Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Revenue	14,817	4,874	5,199
Other Revenue	-0	-	-0
Revenue	14,817	4,874	5,199
Revenue Growth (YoY)	-	-6.26%	-
Cost of Revenue	11,632	2,766	4,151
Gross Profit	3,186	2,108	1,048
Selling, General & Admin	7,961	7,230	7,024
Research & Development	4,639	5,510	4,399
Other Operating Expenses	174.01	172.15	227.69
Operating Expenses	14,360	15,407	13,902
Operating Income	-11,174	-13,299	-12,853
Interest Expense	-3.08	-2.2	-3.24
Interest & Investment Income	743.31	1,227	1,676
Currency Exchange Gain (Loss)	-144.31	7.49	0.97
Other Non Operating Income (Expenses)	1,207	8,044	-1,424
EBT Excluding Unusual Items	-9,371	-4,023	-12,604
Gain (Loss) on Sale of Investments	3,687	-517.37	5.26
Gain (Loss) on Sale of Assets	-13.4	-5.8	-0.14
Asset Writedown	-	-	-195.49
Other Unusual Items	-2,961	-3,133	-625.01
Pretax Income	-8,658	-7,679	-13,419
Net Income	-8,658	-7,679	-13,419
Net Income to Common	-8,658	-7,679	-13,419
Shares Outstanding (Basic)	22	22	21
Shares Outstanding (Diluted)	22	22	21
Shares Change (YoY)	-	1.59%	-
EPS (Basic)	-401.75	-356.48	-632.85
EPS (Diluted)	-401.75	-356.48	-632.85
Free Cash Flow	-13,687	-14,309	-19,456
Free Cash Flow Per Share	-635.09	-664.29	-917.58
Gross Margin	21.50%	43.24%	20.16%
Operating Margin	-75.41%	-272.87%	-247.22%
Profit Margin	-58.43%	-157.56%	-258.10%
Free Cash Flow Margin	-92.37%	-293.60%	-374.22%
EBITDA	-7,520	-10,895	-10,697
EBITDA Margin	-50.75%	-223.55%	-205.74%
D&A For EBITDA	3,654	2,404	2,156
EBIT	-11,174	-13,299	-12,853
EBIT Margin	-75.41%	-272.87%	-247.22%
Advertising Expenses	-	390.07	267.47

Source: S&P Global Market Intelligence. Standard template. Financial Sources.